Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
出版年份 2014 全文链接
标题
Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 32, Issue 25, Pages 2794-2803
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2014-07-22
DOI
10.1200/jco.2013.54.1870
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)
- (2017) L. J. Esserman et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.
- (2017) S. Di Cosimo et al. JOURNAL OF CLINICAL ONCOLOGY
- St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion
- (2013) Nadia Harbeck et al. Breast Care
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Designing Transformative Clinical Trials in the Cancer Genome Era
- (2013) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
- (2013) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- The Cancer Genome Atlas Pan-Cancer analysis project
- (2013) John N Weinstein et al. NATURE GENETICS
- Emerging targeted agents in metastatic breast cancer
- (2013) Dimitrios Zardavas et al. Nature Reviews Clinical Oncology
- PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
- (2013) Sherene Loi et al. PLoS One
- Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse
- (2012) G. Cancello et al. ANNALS OF ONCOLOGY
- Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition
- (2012) Dimitrios Zardavas et al. CURRENT OPINION IN ONCOLOGY
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis
- (2012) Michail Ignatiadis et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
- (2012) Aleix Prat et al. JOURNAL OF CLINICAL ONCOLOGY
- Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
- (2012) C. E. Caldon et al. MOLECULAR CANCER THERAPEUTICS
- Sequence analysis of mutations and translocations across breast cancer subtypes
- (2012) Shantanu Banerji et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
- (2011) G. Viale et al. ANNALS OF ONCOLOGY
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures
- (2011) Cheng Fan et al. BMC Medical Genomics
- Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics
- (2011) E. H. Lips et al. BREAST CANCER RESEARCH AND TREATMENT
- Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer
- (2011) X. Hou et al. CANCER RESEARCH
- ZNF703is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium
- (2011) Daniel G. Holland et al. EMBO Molecular Medicine
- ZNF703gene amplification at 8p12 specifies luminal B breast cancer
- (2011) Fabrice Sircoulomb et al. EMBO Molecular Medicine
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
- (2011) Todd W. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
- (2011) Matthew J. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- (2011) M. Dowsett et al. JNCI-Journal of the National Cancer Institute
- Cancer epigenetics reaches mainstream oncology
- (2011) Manuel Rodríguez-Paredes et al. NATURE MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between breast cancer subtypes and response to neoadjuvant anastrozole
- (2011) Anita K. Dunbier et al. STEROIDS
- Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome
- (2011) David Venet et al. PLoS Computational Biology
- Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy
- (2010) Rohit Bhargava et al. CANCER
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy
- (2010) Andrew Y. Choo et al. CELL CYCLE
- A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
- (2010) T. O. Nielsen et al. CLINICAL CANCER RESEARCH
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
- (2010) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast cancer molecular profiling with single sample predictors: a retrospective analysis
- (2010) Britta Weigelt et al. LANCET ONCOLOGY
- Genome-Wide Analysis of Estrogen Receptor DNA Binding and Tethering Mechanisms Identifies Runx1 as a Novel Tethering Factor in Receptor-Mediated Transcriptional Activation
- (2010) J. D. Stender et al. MOLECULAR AND CELLULAR BIOLOGY
- Delineating Genetic Alterations for Tumor Progression in the MCF10A Series of Breast Cancer Cell Lines
- (2010) Mitsutaka Kadota et al. PLoS One
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
- (2010) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
- (2010) Fiona M. Blows et al. PLOS MEDICINE
- Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
- (2009) Jorma J. de Ronde et al. BREAST CANCER RESEARCH AND TREATMENT
- The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
- (2009) Marieke E. Straver et al. BREAST CANCER RESEARCH AND TREATMENT
- Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer
- (2009) T. W. Miller et al. CANCER RESEARCH
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
- (2009) Judith Hugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- Gene-Expression Signatures in Breast Cancer
- (2009) Christos Sotiriou et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen
- (2008) Marleen Kok et al. BREAST CANCER RESEARCH AND TREATMENT
- Timing is everything: Order of administration of 5-aza 2′ deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity
- (2008) Christine L. Hostetter et al. CANCER LETTERS
- Subtypes of Breast Cancer Show Preferential Site of Relapse
- (2008) M. Smid et al. CANCER RESEARCH
- Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
- (2008) S. Massarweh et al. CANCER RESEARCH
- Targeting the MDM2-p53 Interaction for Cancer Therapy
- (2008) S. Shangary et al. CLINICAL CANCER RESEARCH
- Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy
- (2008) M. Rudas et al. CLINICAL CANCER RESEARCH
- Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
- (2008) M. J. Ellis et al. JNCI-Journal of the National Cancer Institute
- The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics
- (2007) Ahmad Awada et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started